Literature DB >> 15834440

Increased alphaCGRP potency and CGRP-receptor antagonist affinity in isolated hypoxic porcine intramyocardial arteries.

Philip Hasbak1, Karen Eskesen, Søren Schifter, Lars Edvinsson.   

Abstract

1. This study describes the effects of hypoxia on relaxing responses and cAMP production induced by the known vasodilator peptides: alphaCGRP, amylin (AMY) and adrenomedullin (AM) on isolated pig coronary arteries in vitro. 2. Hypoxic incubation increased the vasorelaxant effect of alphaCGRP (four-fold; P<0.05), AMY (3.2-fold; P<0.05), but not significantly for AM (two-fold; NS). 3. Whereas hypoxia had no effect on arterial cAMP levels, it significantly potentiated the production of cAMP stimulated of alphaCGRP and AMY, but not of AM. 4. The antagonist alphaCGRP(8-37) also exerted an increased effect in hypoxia. The Schild plot-derived pK(B) values revealed an increase in the apparent affinity of the antagonist for the CGRP(1) receptor from 7.0 to 7.2 under control conditions versus 8.0 in hypoxia. 5. Removal of endothelium, peptidase inhibitors, preincubation with the adenosine A(2A) receptor antagonist CSC (10(-3) M), the ATP-sensitive K-channel inhibitor glibenclamide (10(-5) M), the cyclooxygenase inhibitor indomethacin (10(-3) M) or NG-monomethyl-L-arginine (10(-4) M) had no effect on the alphaCGRP-induced vasorelaxation in hypoxia; neither did hypoxia influence the levels of CGRP and AM receptor mRNA. 6. We conclude that hypoxic incubation increases the relaxation and cAMP production induced by alphaCGRP and AMY in rings of porcine coronary arteries in vitro. A concomitant release of adenosine, a cyclooxygenase product, an endothelium-derived substance, activation of vascular ATP-sensitive K-channels, peptidase inhibitors or changes in CGRP and AM receptor mRNA cannot account for the changes observed in hypoxia. Moreover, alphaCGRP(8-37) showed increased affinity at the CGRP(1) receptor during hypoxia, possibly due to a conformational change at the CGRP(1) receptor site.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15834440      PMCID: PMC1576180          DOI: 10.1038/sj.bjp.0706232

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  39 in total

1.  CGRP receptors mediating CGRP-, adrenomedullin- and amylin-induced relaxation in porcine coronary arteries. Characterization with 'Compound 1' (WO98/11128), a non-peptide antagonist.

Authors:  P Hasbak; A Sams; S Schifter; J Longmore; L Edvinsson
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

Review 2.  International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors.

Authors:  David R Poyner; Patrick M Sexton; Ian Marshall; David M Smith; Remi Quirion; Walter Born; Roman Muff; Jan A Fischer; Steven M Foord
Journal:  Pharmacol Rev       Date:  2002-06       Impact factor: 25.468

3.  Analysis of the time course for organ culture-induced endothelin ET B receptor upregulation in rat mesenteric arteries.

Authors:  Sebastian Möller; Erik Uddman; Nicola Welsh; Lars Edvinsson; Mikael Adner
Journal:  Eur J Pharmacol       Date:  2002-11-15       Impact factor: 4.432

4.  Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats.

Authors:  M J Mulvany; W Halpern
Journal:  Circ Res       Date:  1977-07       Impact factor: 17.367

5.  Nomenclature for incompletely specified bases in nucleic acid sequences: recommendations 1984.

Authors:  A Cornish-Bowden
Journal:  Nucleic Acids Res       Date:  1985-05-10       Impact factor: 16.971

6.  Functional and molecular characterization of receptor subtypes mediating coronary microvascular dilation to adenosine.

Authors:  T W Hein; W Wang; B Zoghi; M Muthuchamy; L Kuo
Journal:  J Mol Cell Cardiol       Date:  2001-02       Impact factor: 5.000

Review 7.  The role of adenosine in the regulation of coronary blood flow.

Authors:  R M Berne
Journal:  Circ Res       Date:  1980-12       Impact factor: 17.367

Review 8.  The molecular pharmacology of CGRP and related peptide receptor subtypes.

Authors:  C Juaneda; Y Dumont; R Quirion
Journal:  Trends Pharmacol Sci       Date:  2000-11       Impact factor: 14.819

9.  Investigation of CGRP receptors and peptide pharmacology in human coronary arteries. Characterization with a nonpeptide antagonist.

Authors:  Philip Hasbak; Ole Saetrum Opgaard; Karen Eskesen; Søren Schifter; Henrik Arendrup; Jenny Longmore; Lars Edvinsson
Journal:  J Pharmacol Exp Ther       Date:  2003-01       Impact factor: 4.030

10.  Calcitonin gene-related peptide (CGRP) in capsaicin-sensitive substance P-immunoreactive sensory neurons in animals and man: distribution and release by capsaicin.

Authors:  A Franco-Cereceda; H Henke; J M Lundberg; J B Petermann; T Hökfelt; J A Fischer
Journal:  Peptides       Date:  1987 Mar-Apr       Impact factor: 3.750

View more
  2 in total

1.  Vascular reactivity to calcitonin gene-related peptide is enhanced in subtotal nephrectomy-salt induced hypertension.

Authors:  Scott C Supowit; Khurshed A Katki; Travis W Hein; Prakash Gupta; Lih Kuo; Ian M Dickerson; Donald J Dipette
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-06-10       Impact factor: 4.733

Review 2.  Role of CGRP-receptor component protein (RCP) in CLR/RAMP function.

Authors:  Ian M Dickerson
Journal:  Curr Protein Pept Sci       Date:  2013-08       Impact factor: 3.272

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.